المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin

المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Association

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test

المؤلفون: Fareeda Hosein, Veerle de Pril, Jon M. Richards, Jean-Jacques Grob, Vanna Chiarion-Sileni, Henrik Schmidt, Virginia Ferraresi, Alessandro Testori, Omid Hamid, Jeffrey S. Weber, Jedd D. Wolchok, Alexander M.M. Eggermont, Paolo A. Ascierto, Stefan Suciu, Caroline Robert, Michael Smylie, Reinhard Dummer, Michal Kicinski, Céleste Lebbé, Michele Maio

المساهمون: University of Zurich, Eggermont, Alexander M M

المصدر: Eggermont, A M M, Chiarion-Sileni, V, Grob, J J, Dummer, R, Wolchok, J D, Schmidt, H, Hamid, O, Robert, C, Ascierto, P A, Richards, J M, Lebbe, C, Ferraresi, V, Smylie, M, Weber, J S, Maio, M, Hosein, F, de Pril, V, Kicinski, M, Suciu, S & Testori, A 2019, ' Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma : long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial ', European Journal of Cancer, vol. 119, pp. 1-10 . https://doi.org/10.1016/j.ejca.2019.07.001Test

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, 610 Medicine & health, Ipilimumab, Kaplan-Meier Estimate, Placebo, Adjuvant therapy, Metastasis, Long-term results, Melanoma, Phase III trial, Stage III, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Humans, 1306 Cancer Research, Aged, Aged, 80 and over, business.industry, Hazard ratio, 10177 Dermatology Clinic, Cancer, Middle Aged, Prognosis, medicine.disease, Discontinuation, 030104 developmental biology, Chemotherapy, Adjuvant, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Female, 2730 Oncology, business, Follow-Up Studies, medicine.drug

وصف الملف: 806_Eggermont_A._et_al._Adjuvant_ipilimumab_versus_placebo_after_complete_resection_of_stage_III_melanoma_etc._EJC_2019.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::211084f57afa1977a4f55abb0eae48ceTest
https://doi.org/10.1016/j.ejca.2019.07.001Test

المؤلفون: James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser

المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test

المؤلفون: Piotr Rutkowski, Lars Bastholt, Ralf Gutzmer, Claus Garbe, Virginia Ferraresi, Marta Nyakas, Omid Hamid, Joanna Pikiel, Jean-Jacques Grob, Paolo A. Ascierto, Céleste Lebbé, Caroline Robert, Delphine Hennicken, Vanna Chiarion-Sileni, Michael Smylie, Gabriella Liszkay, Florent Grange, Catriona M. McNeil, Luc Thomas, Dirk Schadendorf, Andrzej Mackiewicz, Michele Del Vecchio, Christoph Hoeller, Carmen Loquai, Michele Maio, Inge Marie Svane, Anila Qureshi, Brigitte Dréno, Ana Arance, Laurent Mortier

المساهمون: Istituto Nazionale Tumori Fondazione Pascale [Naples, Italy], Medical Oncology, National Cancer Institute [Milan, Italy], Institut Gustave Roussy ( IGR ), Department of Diagnostics and Cancer Immunology [Poznan, Poland], Greater Poland Cancer Centre [Poznan, Poland]-Poznan Medical University [Poland], Melanoma Oncology Unit [Padova, Italy], Veneto Institute of Oncology IOV-IRCCS [Padua, Italy], Institut d'Investigacions Biomèdiques August Pi I Sunyer [Barcelona, Spain] ( Hospital Clinic ), Immunologie, dermatologie, oncologie, Oncodermatologie, immunologie et cellules souches cutanées ( DIO U976 ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Odense University Hospital [Odense, Denmark], The Angeles Clinic and Research Institute [Los Angeles, CA, USA], Maria Sklodowska-Curie Memorial Cancer Center [Warsaw, Poland], Royal Prince Alfred Hospital ( RPAH - SYDNEY ), Melanoma Institute Australia [Sydney, NSW, Australia], Eberhard Karls University [Tübingen, Germany], University Medical Center [Mainz, Germany], Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ), Département de Dermatologie [CH Lyon-Sud, Pierre-Bénite], Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Hôpital de la Timone [CHU - APHM] ( TIMONE ), National Institute of Oncology [Budapest, Hungary], Oslo University Hospital [Oslo, Norway], Medizinische Hochschule Hannover [Hannover, Germany], Wojewodzkie Centrum Oncologii [Gdańsk, Poland], Département de Dermatologie [CHU de Reims], Centre Hospitalier Universitaire de Reims ( CHU Reims ), Medical University of Vienna [Austria], Istituti Fisioterapici Ospitalieri [Rome, Italy], Cross Cancer Institute [Edmonton, AB, Canada], University Hospital [Essen, Germany], Hôspital Claude Huriez [Lille, France], Herlev Hospital [Herlev, Denmark], University of Copenhagen ( KU ), Bristol-Myers Squibb [Princeton, NJ, USA], Istituto Toscano Tumori [Siena, Italy], University Hospital of Siena [Italy], Bristol-Myers Squibb., Institut Gustave Roussy (IGR), Institut d'Investigacions Biomèdiques August Pi I Sunyer [Barcelona, Spain] (Hospital Clinic ), Oncodermatologie, immunologie et cellules souches cutanées (IDO (U976 / UMR_S 976)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cedars-Sinai Medical Center, Royal Prince Alfred Hospital (RPAH - SYDNEY), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hôpital de la Timone [CHU - APHM] (TIMONE), Oslo University Hospital [Oslo], Centre Hospitalier Universitaire de Reims (CHU Reims), Medizinische Universität Wien = Medical University of Vienna, Hôpital Claude Huriez [Lille], CHU Lille, Herlev and Gentofte Hospital, Bristol-Myers Squibb [Princeton], Bernardo, Elizabeth

المصدر: Ascierto, P A, Del Vecchio, M, Robert, C, Mackiewicz, A, Chiarion-Sileni, V, Arance, A, Lebbe, C, Bastholt, L, Hamid, O, Rutkowski, P, McNeil, C, Garbe, C, Loquai, C, Dreno, B, Thomas, L, Grob, J-J, Liszkay, G, Nyakas, M, Gutzmer, R, Pikiel, J, Grange, F, Hoeller, C, Ferraresi, V, Smylie, M, Schadendorf, D, Mortier, L, Svane, I M, Hennicken, D, Qureshi, A & Maio, M 2017, ' Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma : a randomised, double-blind, multicentre, phase 3 trial ', Lancet Oncology, vol. 18, no. 5, pp. 611-622 . https://doi.org/10.1016/S1470-2045Test(17)30231-0
Articles Lancet Oncol
Articles Lancet Oncol, 2017, 18 (5), pp.611-622. 〈10.1016/S1470-2045(17)30231-0〉
Lancet Oncology
Lancet Oncology, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩
Lancet Oncology, Elsevier, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩

مصطلحات موضوعية: Male, 0301 basic medicine, Medizin, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Clinical endpoint, Melanoma, education.field_of_study, Hazard ratio, Antibodies, Monoclonal, Alanine Transaminase, Middle Aged, Colitis, Intention to Treat Analysis, 3. Good health, Survival Rate, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, medicine.drug, Diarrhea, medicine.medical_specialty, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, Ipilimumab, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Double-Blind Method, Internal medicine, Journal Article, medicine, Humans, Hypophysitis, Adverse effect, education, Survival rate, Aged, Intention-to-treat analysis, business.industry, Surgery, 030104 developmental biology, business, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::227f341e72494aa06d0cdefaa7df2e4fTest
https://doi.org/10.1016/s1470-2045Test(17)30231-0

المؤلفون: Alexander M.M. Eggermont, Stefan Suciu, Céleste Lebbé, Vanna Chiarion-Sileni, Corneel Coens, Michael Smylie, Alessandro Testori, Omid Hamid, Srividya Kotapati, Andrew Bottomley, Jon M. Richards, Jeffrey S. Weber, Reinhard Dummer, Jean-Jacques Grob, Virginia Ferraresi, Michele Maio, Veerle de Pril, Caroline Robert, Henrik Schmidt, Paolo A. Ascierto, Jedd D. Wolchok

المساهمون: University of Zurich, Coens, Corneel

المصدر: Coens, C, Suciu, S, Chiarion-Sileni, V, Grob, J-J, Dummer, R, Wolchok, J D, Schmidt, H, Hamid, O, Robert, C, Ascierto, P A, Richards, J M, Lebbé, C, Ferraresi, V, Smylie, M, Weber, J S, Maio, M, Bottomley, A, Kotapati, S, de Pril, V, Testori, A & Eggermont, A M M 2017, ' Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial ', Lancet Oncology, vol. 18, no. 3, pp. 393-403 . https://doi.org/10.1016/S1470-2045Test(17)30015-3

مصطلحات موضوعية: Male, 0301 basic medicine, Skin Neoplasms, Clinical Trial, Phase III, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Clinical endpoint, Melanoma, Aged, 80 and over, education.field_of_study, 10177 Dermatology Clinic, Antibodies, Monoclonal, Middle Aged, Prognosis, Multicenter Study, Oncology, 030220 oncology & carcinogenesis, Randomized Controlled Trial, 2730 Oncology, Female, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Population, 610 Medicine & health, Ipilimumab, Placebo, Article, Young Adult, 03 medical and health sciences, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Journal Article, medicine, Humans, Comparative Study, Adverse effect, education, Aged, Neoplasm Staging, business.industry, International Agencies, Discontinuation, Surgery, Clinical trial, 030104 developmental biology, Quality of Life, business, Follow-Up Studies

وصف الملف: 678_Coens_C._et_al._Health-related_quality_of_life_with_adjuvant_ipilimumab_versus_placebo_The_Lancet_Oncology_2017.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10cc8cba6fd87ef90f202b6e13871e7bTest
https://doi.org/10.1016/s1470-2045Test(17)30015-3

المؤلفون: Mazhar Ajaz, Laurent Mortier, Inge Marie Svane, Ivan Marquez-Rodas, Thomas Eigentler, Jennifer Lord-Bessen, Paolo A. Ascierto, Elena Grigoryeva, Dirk Schadendorf, Caroline Robert, Linda Rollin, Jacopo Pigozzo, Nicolas Meyer, Michael Smylie, Rene Gonzalez, Alexander M. Menzies, Piotr Rutkowski, Céleste Lebbé, Abdel Saci

المصدر: Journal of Clinical Oncology
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998Test

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Skin Neoplasms, Time Factors, Medizin, Gastroenterology, law.invention, 0302 clinical medicine, Antineoplastic Agents, Immunological, Randomized controlled trial, law, Skin Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Melanoma/drug therapy, Ipilimumab/administration & dosage, Melanoma, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Progression-Free Survival, 3. Good health, Nivolumab/administration & dosage, Nivolumab, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Female, Rapid Communication, medicine.drug, Adult, medicine.medical_specialty, Ipilimumab, Drug Administration Schedule, 03 medical and health sciences, Young Adult, Antineoplastic Agents, Immunological/administration & dosage, Double-Blind Method, Internal medicine, medicine, Humans, Dosing, Progression-free survival, Adverse effect, Aged, Neoplasm Staging, business.industry, Clinical trial, 030104 developmental biology, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7100d36b125a105d0de169d7144e1e3eTest
https://pubmed.ncbi.nlm.nih.gov/30811280Test

المؤلفون: Piotr Rutkowski, Alexander C.J. van Akkooi, Michele Maio, Alfonsus J. M. van den Eertwegh, Christian U. Blank, Nageatte Ibrahim, Adnan Khattak, Paolo A. Ascierto, Rahima Jamal, Ralf Gutzmer, Andrew Haydon, Mikhail Lichinitser, Susana Puig, Victoria Atkinson, Mario Mandalà, Sandrine Marreaud, Caroline Robert, Jean-Jacques Grob, Alexander M.M. Eggermont, Stefan Suciu, Stéphane Dalle, Rutger H. T. Koornstra, Leonel Hernandez-Aya, Shahneen Sandhu, Paul Lorigan, Georgina V. Long, Matteo S. Carlino, James Larkin, Dirk Schadendorf

المساهمون: Universitat de Barcelona, Medical oncology, CCA - Cancer Treatment and quality of life

المصدر: Recercat. Dipósit de la Recerca de Catalunya
instname
The New England Journal of Medicine, 378, 1789-1801
New England Journal of Medicine, 378(19), 1789-1801. Massachussetts Medical Society
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Maio, M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P, Ibrahim, N, Marreaud, S, van Akkooi, A C J, Suciu, S & Robert, C 2018, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma ', New England Journal of Medicine, vol. 378, no. 19, pp. 1789-1801 . https://doi.org/10.1056/NEJMoa1802357Test
Dipòsit Digital de la UB
Universidad de Barcelona
The New England Journal of Medicine, 378, 19, pp. 1789-1801

مصطلحات موضوعية: 0301 basic medicine, Male, Skin Neoplasms, Medizin, Pembrolizumab, Kaplan-Meier Estimate, Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Disease-Free Survival, Double-Blind Method, Female, Humans, Infusions, Intravenous, Intention to Treat Analysis, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Survival Rate, Gastroenterology, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Immunologic, Monoclonal, 80 and over, Humanized, Adjuvant treatment of cancer, education.field_of_study, General Medicine, Local, 030220 oncology & carcinogenesis, Intravenous, medicine.drug, Tractament adjuvant del càncer, medicine.medical_specialty, Infusions, Population, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, Adjuvants, education, Survival rate, business.industry, Cancer, medicine.disease, 030104 developmental biology, Neoplasm Recurrence, Cutaneous melanoma, business, Placebos (Medicine)

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ae9f22b7acc35569131373f281fa946Test
https://doi.org/10.1056/NEJMoa1802357Test

المؤلفون: Céleste Lebbé, Anna Maria Di Giacomo, Helen Gogas, Georgina V. Long, Paolo A. Ascierto, Catalin Mihalcioiu, Francesco Cognetti, Ewa Kalinka-Warzocha, Kerry J. Savage, Cornelia Mauch, Ana Arance, Jasmine I. Rizzo, Lars Ny, Caroline Dutriaux, Piotr Rutkowski, Caroline Robert, Micaela Hernberg, Victoria Atkinson, Vanna Chiarion-Sileni, Benjamin Brady, Inge Marie Svane, Dirk Schadendorf, Jessica C. Hassel, Julie Charles, Laurent Mortier, Catriona M. McNeil, Abdel Saci, Joel Jiang

المصدر: JAMA Oncol

مصطلحات موضوعية: advanced melanoma, Adult, Male, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Time Factors, Adolescent, Dacarbazine, Medizin, Phases of clinical research, Ipilimumab, Pembrolizumab, Placebo, BRAF, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Humans, 030212 general & internal medicine, Nivolumab, wild-type, Antineoplastic Agents, Alkylating, Melanoma, Aged, Aged, 80 and over, business.industry, Hazard ratio, Correction, Middle Aged, medicine.disease, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3c9b0d0b1e4e0e7e07096a725b4e567Test
https://doi.org/10.1001/jamaoncol.2018.4514Test

المؤلفون: David R. Minor, Jeffrey K. Giguere, Matthew H. Taylor, Marc S. Ernstoff, April K.S. Salama, David F. McDermott, Kenneth F. Grossmann, Caroline Robert, Michael A. Postow, Jason Chesney, Christine Horak, Paul Gagnier, Anna C. Pavlick, F. Stephen Hodi, Gerald P. Linette, Patrick A. Ott, Sanjiv S. Agarwala, Nicolas Meyer, Joel Jiang, Montaser Shaheen, Jedd D. Wolchok

المصدر: The Lancet. Oncology. 17(11)

مصطلحات موضوعية: 0301 basic medicine, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Population, Ipilimumab, Article, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, education, Adverse effect, Melanoma, education.field_of_study, business.industry, Hazard ratio, Antibodies, Monoclonal, Surgery, Clinical trial, 030104 developmental biology, Nivolumab, Oncology, 030220 oncology & carcinogenesis, Mutation, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e877f5ff0970a674aa26aefb068c40edTest
https://pubmed.ncbi.nlm.nih.gov/27617662Test

المؤلفون: Jon M. Richards, Jean-Jacques Grob, Veerle de Pril, Paolo A. Ascierto, Virginia Ferraresi, Alessandro Testori, Omid Hamid, Gaetan de Schaetzen, Michele Maio, Henrik Schmidt, Reinhard Dummer, Ravichandra Karra Gurunath, Michael Smylie, C. Lebbé, Jedd D. Wolchok, Cyril Konto, Vanna Chiarion-Sileni, Jeffrey S. Weber, Axel Hoos, Caroline Robert, Alexander M.M. Eggermont, Stefan Suciu

المساهمون: University of Zurich, Eggermont, Alexander M M

المصدر: Eggermont, A M M, Chiarion-Sileni, V, Grob, J-J, Dummer, R, Wolchok, J D, Schmidt, H, Hamid, O, Robert, C, Ascierto, P A, Richards, J M, Lebbé, C, Ferraresi, V, Smylie, M, Weber, J S, Maio, M, Konto, C, Hoos, A, de Pril, V, Gurunath, R K, de Schaetzen, G, Suciu, S & Testori, A 2015, ' Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial ', Lancet Oncology, vol. 16, no. 5, pp. 522-30 . https://doi.org/10.1016/S1470-2045Test(15)70122-1

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Ipilimumab, 610 Medicine & health, Placebo, Disease-Free Survival, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, medicine, Adjuvant therapy, Clinical endpoint, Humans, Melanoma, Aged, Intention-to-treat analysis, business.industry, Hazard ratio, Antibodies, Monoclonal, 10177 Dermatology Clinic, Middle Aged, medicine.disease, Combined Modality Therapy, Surgery, Clinical trial, Oncology, Lymphatic Metastasis, Female, 2730 Oncology, Neoplasm Recurrence, Local, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c25866cb1bdc390a7c77b04fd67dd6eTest
https://www.zora.uzh.ch/id/eprint/113040Test/